Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11691971 Naphthyridinone compounds as JAK2 V617F inhibitors

Patent 11691971 was granted and assigned to Incyte on July, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Incyte
Incyte
0
Date Filed
June 17, 2021
0
Date of Patent
July 4, 2023
0
Patent Applicant
Incyte
Incyte
0
Patent Application Number
17350470
0
Patent Citations
‌
US Patent 8785639 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
0
‌
US Patent 9115133 Substituted fused tricyclic compounds, compositions and medicinal applications thereof
0
‌
US Patent 9233985 Arginase inhibitors as therapeutics
0
‌
US Patent 9321730 Method of making and administering quinoline derivatives as anti-cancer agents
0
‌
US Patent 9493419 Quinoline derivatives as anti-cancer agents
0
‌
US Patent 10065974 Compositions and methods for inhibiting arginase activity
0
‌
US Patent 10155987 Methods of predicting resistance to JAK inhibitor therapy
0
‌
US Patent 10377759 Brk inhibitory compound
0
‌
US Patent 10287303 Compositions and methods for inhibiting arginase activity
0
‌
US Patent 7429456 Identification of a JAK2 mutation in Polycythemia Vera
0
•••
Patent Citations Received
‌
US Patent 12084430 Tricyclic urea compounds as JAK2 V617F inhibitors
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11691971
0
Patent Primary Examiner
‌
Niloofar Rahmani
0
CPC Code
‌
C07D 471/04
0

Find more entities like US Patent 11691971 Naphthyridinone compounds as JAK2 V617F inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo